Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 5/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 4/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.35 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.35 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.35 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.35 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.35 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.34 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1973288 | 1.00 | CHRM4 (0.35) | CHRM4CHRNB2CHRNA4CHRNB1CHRNB4 | |
| SCHEMBL314384 | 0.91 | CHRNA7 (0.37) | CHRM4GRIN1GRIN2BFFAR4KMT2A | |
| SCHEMBL314385 | 0.91 | CHRNA7 (0.37) | CHRM4GRIN1GRIN2BFFAR4KMT2A | |
| SCHEMBL3999819 | 0.84 | CHRNB2 (0.35) | CHRNB2CHRNA4 | |
| SCHEMBL3999824 | 0.84 | CHRNB2 (0.35) | CHRNB2CHRNA4 | |
| SCHEMBL1974836 | 0.83 | CYP2A6 (0.37) | CHRM4CHRNB2CHRNA4 | |
| SCHEMBL1974833 | 0.83 | CYP2A6 (0.37) | CHRM4CHRNB2CHRNA4 | |
| SCHEMBL315484 | 0.83 | KDM1A (0.34) | CHRM4GRIN1GRIN2BFFAR4 | |
| SCHEMBL315485 | 0.83 | KDM1A (0.34) | CHRM4GRIN1GRIN2BFFAR4 | |
| SCHEMBL1974804 | 0.83 | CHRNB2 (0.35) | CHRM4CHRNB2CHRNA4GRIN1GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1668021-B1 | NOVEL THIOXYLOSE COMPOUNDS, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AND USE THEREOF IN THERAPEUTICS | FOURNIER LAB SA (FR) | 2011-06-22 | — | — | EP | disclosed |
| US-7470671-B2 | Thioxylose compounds, preparation method thereof, pharmaceutical compositions containing same and use thereof in therapeutics | LABORATOIRE FOURNIER (FR) | 2008-12-30 | — | — | US | disclosed |
| US-20070054955-A1 | Novel thioxylose compounds, preparation method thereof, pharmaceutical compositions containing same and use thereof in therepeutics. | LABORATOIRES FOURNIER S.A. (FR) | 2007-03-08 | — | — | US | disclosed |
| EP-1668021-A2 | NOVEL THIOXYLOSE COMPOUNDS, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AND USE THEREOF IN THERAPEUTICS | LABORATOIRES FOURNIER S.A. (FR) | 2006-06-14 | — | — | EP | disclosed |
| WO-2005030785-A2 | NOVEL THIOXYLOSE COMPOUNDS, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AND USE THEREOF IN THERAPEUTICS | LABORATOIRES FOURNIER S.A. (FR) | 2005-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054955-A1 | Novel thioxylose compounds, preparation method thereof, pharmaceutical compositions containing same and use thereof in therepeutics. | NOTUM, STS, AGPS | CHRM4 4150/4885CHRNB2 4512/4885CHRNA4 4795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.